Skip to Content

Avaglim

Active Substance: rosiglitazone / glimepiride
Common Name: rosiglitazone / glimepiride
ATC Code: A10BD04
Marketing Authorisation Holder: SmithKline Beecham Ltd
Active Substance: rosiglitazone / glimepiride
Status: Withdrawn
Authorisation Date: 2006-06-27
Therapeutic Area: Diabetes Mellitus, Type 2
Pharmacotherapeutic Group: Drugs used in diabetes

Therapeutic Indication

AVAGLIM is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control on optimal dosage of sulphonylurea monotherapy, and for whom metformin is inappropriate because of contraindication or intolerance.

The marketing authorisation for Avaglim has been withdrawn for safety reasons following a decision by the European Commission.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide